AngioDynamics (NSDQ:ANGO) won a green light from the FDA for a clinical trial of its NanoKnife device for treating prostate cancer.
AngioDynamics
AngioDynamics lets sales manager Panzer go | Personnel Moves
keys: angiodynamics, cfo, alan panzer
Albany, N.Y.-based AngioDynamics (NSDQ:ANGO) said Alan Panzer, its general manager of U.S. sales, will no longer be with the company as of July 31, 2013.
Medical device tax: AdvaMed takes the repeal fight to the people
Sluggish results continue to roll in across the med-tech sector
The FDA sends medtech reviewers into the field | MassDevice.com On Call
MASSDEVICE ON CALL — The FDA is looking for medical device companies to participate in its "Experiential Learning Program," so that the agency’s reviewers can get a 1st-hand look into medtech design and manufacturing.
Participating companies would host tours for healthcare regulators as part of a training mechanism to give the reviewers a sense of the medtech development life-cycle and the "challenges faced throughout development, testing, manufacturing, and clinical use," according to an FDA notice.
AngioDynamics names senior VP & CTO | Personnel Moves
AngioDynamics’ executive VP & CFO retires | Personnel Moves
AngioDynamics loses EVP & CFO
Albany, N.Y.-based AngioDynamics’ executive vice president & CFO Joseph Gersuk retired from the company, effective January 31, 2013.
St. Jude Medical-backed Nanostim drums up $10M | Wall Street Beat
Nanostim, the Sunnyvale, Calif.-based company that’s developing a leadless pacemaker, raised $10 million in an equity and options deal, according to a regulatory filing.
AngioDynamics offers updates on fleet of lawsuits
In additional to touting a 53% spike in sales, AngioDynamics’ (NSDQ:ANGO) 1st-quarter earnings report detailed a raft of ongoing lawsuits over infringed patents, jilted employees and soured distribution agreements.
AngioDynamics slides hard on Street-beating quarter, earnings-lowering acquisition
AngioDynamics (NSDQ:ANGO) shares took a dive as the company released its 1st quarter earnings report, announced an acquisition worth at least $55 million over the next 5 years and disclosed a shareholder class action lawsuit filed late last month.